TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer
Brief Summary: The aim is to assess the relative efficacy of S-1 de-escalation therapy vs. continuation of chemotherapy after induction therapy in patients with metastatic esophagogastric cancer in terms of overall survival.


Options:
A: Arm Label: Trastuzumab, Fluoropyrimidine, Cisplatin; Type: EXPERIMENTAL; Interventions: Drug: Trastuzumab, Drug: Fluorouracil, Drug: Cisplatin, Drug: Capecitabine | Arm Label: Fluoropyrimidine, Cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluorouracil, Drug: Cisplatin, Drug: Capecitabine | Intervention Type: DRUG; Name: Trastuzumab; Assigned to Arm(s): Trastuzumab, Fluoropyrimidine, Cisplatin | Intervention Type: DRUG; Name: Fluorouracil; Assigned to Arm(s): Fluoropyrimidine, Cisplatin, Trastuzumab, Fluoropyrimidine, Cisplatin | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Fluoropyrimidine, Cisplatin, Trastuzumab, Fluoropyrimidine, Cisplatin | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Fluoropyrimidine, Cisplatin, Trastuzumab, Fluoropyrimidine, Cisplatin
B: Arm Label: S-1+Cisplatin; Type: EXPERIMENTAL; Interventions: Drug: S-1 (Tegafur+Gimeracil+Oteracil) /cisplatin (investigational arm) | Arm Label: 5FU+Cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluorouracil/cisplatin (control arm) | Intervention Type: DRUG; Name: S-1 (Tegafur+Gimeracil+Oteracil) /cisplatin (investigational arm); Assigned to Arm(s): S-1+Cisplatin | Intervention Type: DRUG; Name: Fluorouracil/cisplatin (control arm); Assigned to Arm(s): 5FU+Cisplatin
C: Arm Label: Arm A: De-escalation therapy; Type: EXPERIMENTAL; Interventions: Drug: S-1 de-escalation | Arm Label: Arm B: Chemotherapy by Investigator's choice; Type: EXPERIMENTAL; Interventions: Drug: Chemotherapy by Investigator's choice | Intervention Type: DRUG; Name: S-1 de-escalation; Assigned to Arm(s): Arm A: De-escalation therapy | Intervention Type: DRUG; Name: Chemotherapy by Investigator's choice; Assigned to Arm(s): Arm B: Chemotherapy by Investigator's choice
D: Arm Label: 1- Docetaxel plus Oxaliplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel, Drug: oxaliplatin | Arm Label: 2- Docetaxel plus oxaliplatin plus cetuximab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel, Drug: cetuximab, Drug: oxaliplatin | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): 1- Docetaxel plus Oxaliplatin, 2- Docetaxel plus oxaliplatin plus cetuximab | Intervention Type: DRUG; Name: cetuximab; Assigned to Arm(s): 2- Docetaxel plus oxaliplatin plus cetuximab | Intervention Type: DRUG; Name: oxaliplatin; Assigned to Arm(s): 1- Docetaxel plus Oxaliplatin, 2- Docetaxel plus oxaliplatin plus cetuximab

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Double-blind Controlled Trial of Use of Dydrogesterone in Women With Threatened Miscarriage in the First Trimester
Brief Summary: The aim of this study is to determine whether the dydrogesterone therapy is associated with reduction in miscarriage in women with first trimester threatened miscarriage. The hypothesis is that the dydrogesterone therapy will significantly reduce the risk of miscarriage in women with threatened miscarriage.


Options:
A: Arm Label: Dydrogesterone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dydrogesterone | Arm Label: Placebo pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dydrogesterone; Assigned to Arm(s): Dydrogesterone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo pill
B: Arm Label: Lipoic acid; Type: EXPERIMENTAL; Interventions: Device: Lipoic acid | Arm Label: Progesterone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Progesterone | Intervention Type: DEVICE; Name: Lipoic acid; Assigned to Arm(s): Lipoic acid | Intervention Type: DRUG; Name: Progesterone; Assigned to Arm(s): Progesterone
C: Arm Label: mifepristone+misoprostol; Type: EXPERIMENTAL; Interventions: Drug: mifepristone+misoprostol | Arm Label: misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: misoprostol+placebo | Intervention Type: DRUG; Name: mifepristone+misoprostol; Assigned to Arm(s): mifepristone+misoprostol | Intervention Type: DRUG; Name: misoprostol+placebo; Assigned to Arm(s): misoprostol
D: Arm Label: 17 alfa hydroxy Progesterone caproate; Type: ACTIVE_COMPARATOR; Interventions: Drug: 17 alpha-hydroxy progesterone caproate | Arm Label: Micronized Progesterone; Type: ACTIVE_COMPARATOR; Interventions: Drug: micronized Progesterone | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Control | Intervention Type: DRUG; Name: 17 alpha-hydroxy progesterone caproate; Assigned to Arm(s): 17 alfa hydroxy Progesterone caproate | Intervention Type: DRUG; Name: micronized Progesterone; Assigned to Arm(s): Micronized Progesterone | Intervention Type: PROCEDURE; Name: Control; Assigned to Arm(s): Control

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Double-blind Controlled Trial of Use of Dydrogesterone in Women With Threatened Miscarriage in the First Trimester
Brief Summary: The aim of this study is to determine whether the dydrogesterone therapy is associated with reduction in miscarriage in women with first trimester threatened miscarriage. The hypothesis is that the dydrogesterone therapy will significantly reduce the risk of miscarriage in women with threatened miscarriage.


Options:
A: Arm Label: Dydrogesterone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dydrogesterone | Arm Label: Placebo pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dydrogesterone; Assigned to Arm(s): Dydrogesterone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo pill
B: Arm Label: Vaginal progesterone group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Progesterone | Arm Label: No progesterone group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Progesterone; Assigned to Arm(s): Vaginal progesterone group
C: Arm Label: Lipoic acid; Type: EXPERIMENTAL; Interventions: Device: Lipoic acid | Arm Label: Progesterone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Progesterone | Intervention Type: DEVICE; Name: Lipoic acid; Assigned to Arm(s): Lipoic acid | Intervention Type: DRUG; Name: Progesterone; Assigned to Arm(s): Progesterone
D: Arm Label: Oral dydrogesterone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral dydrogesterone | Arm Label: Crinone 8% vaginal gel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Crinone 8% gel | Intervention Type: DRUG; Name: Oral dydrogesterone; Assigned to Arm(s): Oral dydrogesterone | Intervention Type: DRUG; Name: Crinone 8% gel; Assigned to Arm(s): Crinone 8% vaginal gel

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dry Eye Assessment and Management Study
Brief Summary: The objective of the DREAM study is to evaluate the effectiveness and safety of supplementation with omega-3 fatty acids in relieving the symptoms of moderate to severe dry eye disease.


Options:
A: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Other: Inactive Capsule | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Hydroeye | Intervention Type: DIETARY_SUPPLEMENT; Name: Hydroeye; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Inactive Capsule; Assigned to Arm(s): 1
B: Arm Label: Normal; Type: N/A; Interventions: N/A | Arm Label: Dry Eye Disease; Type: N/A; Interventions: N/A
C: Arm Label: Omega-3 supplements; Type: EXPERIMENTAL; Interventions: Drug: Omega-3 supplements | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Omega-3 supplements; Assigned to Arm(s): Omega-3 supplements | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: SB; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Sea buckthorn (Hippophaë rhamnoides) oil | Arm Label: PL; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo comparison | Intervention Type: DIETARY_SUPPLEMENT; Name: Sea buckthorn (Hippophaë rhamnoides) oil; Assigned to Arm(s): SB | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo comparison; Assigned to Arm(s): PL

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dry Eye Assessment and Management Study
Brief Summary: The objective of the DREAM study is to evaluate the effectiveness and safety of supplementation with omega-3 fatty acids in relieving the symptoms of moderate to severe dry eye disease.


Options:
A: Arm Label: 1.; Type: EXPERIMENTAL; Interventions: Drug: DHA (Docosahexaenoic Acid) | Arm Label: 2.; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: DHA (Docosahexaenoic Acid); Assigned to Arm(s): 1. | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2.
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: omega-3 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: omega-3, Behavioral: multi-domain intervention | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: multi-domain intervention, Drug: Placebo | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: omega-3; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: multi-domain intervention; Assigned to Arm(s): 2, 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3, 4
C: Arm Label: Omega 3 recipient arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Omega 3 Fish Oil supplements | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Omega 3 Fish Oil supplements; Assigned to Arm(s): Omega 3 recipient arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Omega-3 supplements; Type: EXPERIMENTAL; Interventions: Drug: Omega-3 supplements | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Omega-3 supplements; Assigned to Arm(s): Omega-3 supplements | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prophylactic Wound VACuum Therapy to Decrease Rates of Cesarean Section in the Obese Population
Brief Summary: This study will assess whether a negative pressure wound vacuum therapy (NPWT) on closed incisions decreases the risk of wound complications among obese patients after cesarean section

All patients having a cesarean section in labor or presenting to the triage unit and requiring a cesarean section will be eligible

Main study intervention: this involves the use of a negative pressure wound vacuum therapy on a closed incision.


Options:
A: Arm Label: Negative pressure dressing; Type: EXPERIMENTAL; Interventions: Device: Negative pressure dressing | Arm Label: Standard dressing; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard wound dressing | Intervention Type: DEVICE; Name: Negative pressure dressing; Assigned to Arm(s): Negative pressure dressing | Intervention Type: DEVICE; Name: Standard wound dressing; Assigned to Arm(s): Standard dressing
B: Arm Label: Negative Pressure Wound Therapy; Type: EXPERIMENTAL; Interventions: Device: Negative pressure wound therapy | Arm Label: Standard dressing; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Negative pressure wound therapy; Assigned to Arm(s): Negative Pressure Wound Therapy
C: Arm Label: High Risk - Prevena Care; Type: EXPERIMENTAL; Interventions: Device: Prevena Care | Arm Label: High Risk - Dry Gauze Dressing Care; Type: ACTIVE_COMPARATOR; Interventions: Device: Dry gauze dressing care | Arm Label: Low Risk - Dry Gauze Dressing Care; Type: ACTIVE_COMPARATOR; Interventions: Device: Dry gauze dressing care | Intervention Type: DEVICE; Name: Prevena Care; Assigned to Arm(s): High Risk - Prevena Care | Intervention Type: DEVICE; Name: Dry gauze dressing care; Assigned to Arm(s): High Risk - Dry Gauze Dressing Care, Low Risk - Dry Gauze Dressing Care
D: Arm Label: Closed Incision Wound vacuum (Prevena); Type: EXPERIMENTAL; Interventions: Device: Closed incision wound vacuum (Prevena) | Arm Label: Routine Wound Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Closed incision wound vacuum (Prevena); Assigned to Arm(s): Closed Incision Wound vacuum (Prevena)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prophylactic Wound VACuum Therapy to Decrease Rates of Cesarean Section in the Obese Population
Brief Summary: This study will assess whether a negative pressure wound vacuum therapy (NPWT) on closed incisions decreases the risk of wound complications among obese patients after cesarean section

All patients having a cesarean section in labor or presenting to the triage unit and requiring a cesarean section will be eligible

Main study intervention: this involves the use of a negative pressure wound vacuum therapy on a closed incision.


Options:
A: Arm Label: Prevena device (Group A); Type: EXPERIMENTAL; Interventions: Device: Prevena device (Group A) | Arm Label: Conventional dressing (Group B); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Prevena device (Group A); Assigned to Arm(s): Prevena device (Group A)
B: Arm Label: Closed Incision Wound vacuum (Prevena); Type: EXPERIMENTAL; Interventions: Device: Closed incision wound vacuum (Prevena) | Arm Label: Routine Wound Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Closed incision wound vacuum (Prevena); Assigned to Arm(s): Closed Incision Wound vacuum (Prevena)
C: Arm Label: Negative Pressure Wound Therapy; Type: EXPERIMENTAL; Interventions: Device: Negative Pressure Wound Therapy, Other: Usual Care of Surgical Wound | Arm Label: Usual Care of Surgical Wound; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care of Surgical Wound | Intervention Type: DEVICE; Name: Negative Pressure Wound Therapy; Assigned to Arm(s): Negative Pressure Wound Therapy | Intervention Type: OTHER; Name: Usual Care of Surgical Wound; Assigned to Arm(s): Negative Pressure Wound Therapy, Usual Care of Surgical Wound
D: Arm Label: Negative Pressure Wound Therapy; Type: EXPERIMENTAL; Interventions: Device: Negative pressure wound therapy | Arm Label: Standard dressing; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Negative pressure wound therapy; Assigned to Arm(s): Negative Pressure Wound Therapy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prophylactic Wound VACuum Therapy to Decrease Rates of Cesarean Section in the Obese Population
Brief Summary: This study will assess whether a negative pressure wound vacuum therapy (NPWT) on closed incisions decreases the risk of wound complications among obese patients after cesarean section

All patients having a cesarean section in labor or presenting to the triage unit and requiring a cesarean section will be eligible

Main study intervention: this involves the use of a negative pressure wound vacuum therapy on a closed incision.


Options:
A: Arm Label: Closed Incision Wound vacuum (Prevena); Type: EXPERIMENTAL; Interventions: Device: Closed incision wound vacuum (Prevena) | Arm Label: Routine Wound Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Closed incision wound vacuum (Prevena); Assigned to Arm(s): Closed Incision Wound vacuum (Prevena)
B: Arm Label: Negative pressure dressing; Type: EXPERIMENTAL; Interventions: Device: Negative pressure dressing | Arm Label: Standard dressing; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard wound dressing | Intervention Type: DEVICE; Name: Negative pressure dressing; Assigned to Arm(s): Negative pressure dressing | Intervention Type: DEVICE; Name: Standard wound dressing; Assigned to Arm(s): Standard dressing
C: Arm Label: Prevena device (Group A); Type: EXPERIMENTAL; Interventions: Device: Prevena device (Group A) | Arm Label: Conventional dressing (Group B); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Prevena device (Group A); Assigned to Arm(s): Prevena device (Group A)
D: Arm Label: High Risk - Prevena Care; Type: EXPERIMENTAL; Interventions: Device: Prevena Care | Arm Label: High Risk - Dry Gauze Dressing Care; Type: ACTIVE_COMPARATOR; Interventions: Device: Dry gauze dressing care | Arm Label: Low Risk - Dry Gauze Dressing Care; Type: ACTIVE_COMPARATOR; Interventions: Device: Dry gauze dressing care | Intervention Type: DEVICE; Name: Prevena Care; Assigned to Arm(s): High Risk - Prevena Care | Intervention Type: DEVICE; Name: Dry gauze dressing care; Assigned to Arm(s): High Risk - Dry Gauze Dressing Care, Low Risk - Dry Gauze Dressing Care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Use of Abdominal Binders in Patients Undergoing Cesarean Sections: A Randomized Controlled Trial
Brief Summary: To see if the use of Abdominal Binders improves patients out comes after cesarean delivery


Options:
A: Arm Label: SofPulse nonfunctional device.; Type: PLACEBO_COMPARATOR; Interventions: Device: SofPulse | Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Device: SofPulse | Intervention Type: DEVICE; Name: SofPulse; Assigned to Arm(s): Active, SofPulse nonfunctional device.
B: Arm Label: abdominal binder; Type: ACTIVE_COMPARATOR; Interventions: Device: abdominal Binder | Arm Label: No Abdominal Binder; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: abdominal Binder; Assigned to Arm(s): abdominal binder
C: Arm Label: Music therapy; Type: EXPERIMENTAL; Interventions: Other: Music group, Other: Non music group | Arm Label: No music group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Music group; Assigned to Arm(s): Music therapy | Intervention Type: OTHER; Name: Non music group; Assigned to Arm(s): Music therapy
D: Arm Label: Active device; Type: ACTIVE_COMPARATOR; Interventions: Device: Pulsed electromagnetic field device (ActiPatch TM) | Arm Label: Placebo - inactive device; Type: PLACEBO_COMPARATOR; Interventions: Device: Inactive pulsed electromagnetic field device (ActiPatch TM) | Intervention Type: DEVICE; Name: Pulsed electromagnetic field device (ActiPatch TM); Assigned to Arm(s): Active device | Intervention Type: DEVICE; Name: Inactive pulsed electromagnetic field device (ActiPatch TM); Assigned to Arm(s): Placebo - inactive device

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Dark Chocolate on Blood Pressure in Mildly Hypertensive Individuals
Brief Summary: The evidence linking chocolate with lowered blood pressure has been observed. However, the interventions have been short, at most 4 weeks. The aim of this study is to find out if the habitual consumption of dark chocolate for 8 weeks has an effect on blood pressure. Also, more insight to the mechanisms linking chocolate to individual healt-responses is needed.


Options:
A: Arm Label: Low- polyphenol diet; Type: OTHER; Interventions: Other: Two portions of fruit and vegetables per day (excluding berries and dark chocolate) | Arm Label: High-polyphenol diet; Type: ACTIVE_COMPARATOR; Interventions: Other: Six portions of fruit and vegetables per day (one of which must be berries) and 50g dark chocolate. | Intervention Type: OTHER; Name: Two portions of fruit and vegetables per day (excluding berries and dark chocolate); Assigned to Arm(s): Low- polyphenol diet | Intervention Type: OTHER; Name: Six portions of fruit and vegetables per day (one of which must be berries) and 50g dark chocolate.; Assigned to Arm(s): High-polyphenol diet
B: Arm Label: Dark chocolate, dietary counselling; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Dark chocolate | Arm Label: Dietary counselling; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Dark chocolate, Other: Dietary counselling | Intervention Type: DIETARY_SUPPLEMENT; Name: Dark chocolate; Assigned to Arm(s): Dark chocolate, dietary counselling, Dietary counselling | Intervention Type: OTHER; Name: Dietary counselling; Assigned to Arm(s): Dietary counselling
C: Arm Label: Dark chocolate; Type: EXPERIMENTAL; Interventions: Other: Flavanol-rich dark chocolate | Arm Label: Placebo chocolate; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo Chocolate | Intervention Type: OTHER; Name: Flavanol-rich dark chocolate; Assigned to Arm(s): Dark chocolate | Intervention Type: OTHER; Name: Placebo Chocolate; Assigned to Arm(s): Placebo chocolate
D: Arm Label: flavanol rich intervention; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Flavanol (410 mg) | Arm Label: flavanol free intervention; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Control (no flavanols) | Intervention Type: DIETARY_SUPPLEMENT; Name: Flavanol (410 mg); Assigned to Arm(s): flavanol rich intervention | Intervention Type: DIETARY_SUPPLEMENT; Name: Control (no flavanols); Assigned to Arm(s): flavanol free intervention

Answer: B